Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Assets Average (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Assets Average for 4 consecutive years, with $510.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Assets Average changed N/A to $510.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $510.0 million, a N/A change, with the full-year FY2024 number at $468.5 million, up 16.47% from a year prior.
  • Assets Average was $510.0 million for Q2 2025 at Centessa Pharmaceuticals, down from $552.3 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $593.3 million in Q4 2024 to a low of $368.8 million in Q4 2023.
  • A 4-year average of $505.3 million and a median of $507.1 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: dropped 20.14% in 2023, then soared 60.86% in 2024.
  • Centessa Pharmaceuticals' Assets Average stood at $461.8 million in 2022, then fell by 20.14% to $368.8 million in 2023, then skyrocketed by 60.86% to $593.3 million in 2024, then dropped by 14.04% to $510.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Assets Average are $510.0 million (Q2 2025), $552.3 million (Q1 2025), and $593.3 million (Q4 2024).